1. Home
  2. CNS vs RLAY Comparison

CNS vs RLAY Comparison

Compare CNS & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

SELL

Current Price

$68.86

Market Cap

4.4B

Sector

Finance

ML Signal

SELL

Logo Relay Therapeutics Inc.

RLAY

Relay Therapeutics Inc.

SELL

Current Price

$17.36

Market Cap

4.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CNS
RLAY
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.1B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
CNS
RLAY
Price
$68.86
$17.36
Analyst Decision
Hold
Strong Buy
Analyst Count
3
13
Target Price
★ $74.67
$27.58
AVG Volume (30 Days)
241.0K
★ 3.1M
Earning Date
10-15-2026
11-05-2026
Dividend Yield
★ 3.88%
N/A
EPS Growth
N/A
★ 31.78
EPS
★ 1.77
N/A
Revenue
★ $427,536,000.00
$15,355,000.00
Revenue This Year
$10.54
N/A
Revenue Next Year
$10.14
$60.51
P/E Ratio
$38.99
★ N/A
Revenue Growth
4.07
★ 53.44
52 Week Low
$58.39
$5.95
52 Week High
$86.56
$21.27

Technical Indicators

Market Signals
Indicator
CNS
RLAY
Relative Strength Index (RSI) 23.08 41.36
Support Level $68.02 $11.68
Resistance Level $69.40 $17.40
Average True Range (ATR) 1.96 0.89
MACD -0.28 -0.06
Stochastic Oscillator 5.00 19.53

Price Performance

Historical Comparison
CNS
RLAY

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

Share on Social Networks: